Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 373Neoplasms 323Neoplasm Metastasis 286Leukemia, Myeloid, Acute 277Breast Neoplasms 271Colorectal Neoplasms 238Melanoma 194Ovarian Neoplasms 191Recurrence 183Multiple Myeloma 179Prostatic Neoplasms 156Lung Neoplasms 156Pancreatic Neoplasms 153Squamous Cell Carcinoma of Head and Neck 150Lymphoma, Non-Hodgkin 146Glioblastoma 145Triple Negative Breast Neoplasms 120Myelodysplastic Syndromes 114Carcinoma, Renal Cell 111Stomach Neoplasms 110Glioma 108Advanced Solid Tumors 106Brain Neoplasms 105Precursor Cell Lymphoblastic Leukemia-Lymphoma 103Lymphoma, Large B-Cell, Diffuse 101Lymphoma 100Lymphoma, B-Cell 98Carcinoma, Hepatocellular 95Endometrial Neoplasms 92Lymphoma, Follicular 91

Interventions

pembrolizumab 1omega-N-Methylarginine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × DNA Repair-Deficiency Disorders × 1 year × Clear all
NCT03236935 2026-04-09

Phase Ib of L-NMMA and Pembrolizumab

The Methodist Hospital Research Institute

Phase 1 Completed
12 enrolled 15 charts
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, DNA Repair-Deficiency Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡